NAC

Two studies demonstrated that NAC supplementation significantly enhanced immune function and nearly fully restored natural killer (NK) cell activity in subjects with immune deficiencies.

Administration of 1200 mg NAC daily showed positive impact on positive, negative, general, and total psychopathological symptoms in schizophrenia patients, along with improvement of cognitive performance.

A double-blinded, randomized, placebo-controlled trial with 120 COPD patients (58 treated with 600 mg NAC twice daily, 62 placebo) demonstrated significant improvement in small airway function and reduction in disease exacerbation frequency.

Meta-analysis showed that NAC administered for 24 weeks or more improves schizophrenia symptoms and cognitive domain of working memory, with daily doses ranging from 600-3600 mg.

Administration of 1200 mg NAC daily showed positive impact on positive, negative, general, and total psychopathological symptoms in schizophrenia patients, along with improvement of cognitive performance.

Meta-analysis showed that NAC administered for 24 weeks or more improves schizophrenia symptoms and cognitive domain of working memory, with daily doses ranging from 600-3600 mg.

Administration of 1200 mg NAC daily showed positive impact on positive, negative, general, and total psychopathological symptoms in schizophrenia patients, along with improvement of cognitive performance.

Meta-analysis showed that NAC administered for 24 weeks or more improves schizophrenia symptoms and cognitive domain of working memory, with daily doses ranging from 600-3600 mg.

Two studies demonstrated that NAC supplementation significantly enhanced immune function and nearly fully restored natural killer (NK) cell activity in subjects with immune deficiencies.

Uncontrolled studies in healthy volunteers showed significant homocysteine-lowering effects with acute NAC administration of 7200 mg within 24 hours (44% reduction) and 1200-4000 mg single doses (22% reduction).

A double-blinded, randomized, placebo-controlled trial with 120 COPD patients (58 treated with 600 mg NAC twice daily, 62 placebo) demonstrated significant improvement in small airway function and reduction in disease exacerbation frequency.

A double-blinded, randomized, placebo-controlled trial with 120 COPD patients (58 treated with 600 mg NAC twice daily, 62 placebo) demonstrated significant improvement in small airway function and reduction in disease exacerbation frequency.

A double-blinded, randomized, placebo-controlled trial with 120 COPD patients (58 treated with 600 mg NAC twice daily, 62 placebo) demonstrated significant improvement in small airway function and reduction in disease exacerbation frequency.

A double-blinded, randomized, placebo-controlled trial with 120 COPD patients (58 treated with 600 mg NAC twice daily, 62 placebo) demonstrated significant improvement in small airway function and reduction in disease exacerbation frequency.